Submitted for Publication: December 31, 2014; final revision received March 18, 2015; accepted March 24, 2015.
Published Online: June 3, 2015. doi:10.1001/jamapsychiatry.2015.0533.
Study concept and design: Kimoto, Lewis.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Kimoto, Zaki, Lewis.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kimoto, Zaki.
Obtained funding: Kimoto, Lewis.
Administrative, technical, or material support: Bazmi, Lewis.
Study supervision: Bazmi, Lewis.
Conflict of Interest Disclosures: Dr Lewis reports receiving investigator-initiated research support from Bristol-Myers Squibb and Pfizer and in 2012-2014 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol-Myers Squibb, and Concert Pharmaceuticals. No other disclosures are reported.
Funding/Support: This work was supported by National Institutes of Health grants MH043784 and MH084053 (Dr Lewis) from the National Institute of Mental Health and Nara Medical University (Dr Kimoto).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Mary Brady, BS (University of Pittsburgh), assisted with editing the graphics, and Dominique Arion, PhD (University of Pittsburgh), assisted in providing the results of microarray analyses. There was no financial compensation.